From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO – LUNG CANCER
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Post Congress Wrap-Up Meeting
On Wednesday 5th of July 2023, Dr Mariana Brandao has moderated a panel discussion with esteemed Belgian experts, Prof Dr Sebahat Ocak and Dr Charlotte Debondt. Together, they explored the practical applications of the latest research findings in Lung Cancer.
This dynamic and interactive session provides valuable insights for healthcare professionals.
Daily highlights in lung cancer
Dr. Mariana Brandao from the Institut Jules Bordet in Brussels provided insightful commentary on three interesting presentations from the oral abstract session on metastatic non small cell lung cancer.
Professor Benjamin Besse and Dr. Mariana Brandao delve deeper into the results of the CHRYSALIS-2 study, which is a phase 1/1b study that aims to evaluate the efficacy of amivantamabam
Prof. Christophe Dooms from UZ Gasthuisberg in Leuven discussed several important studies presented at the conference. One of the studies mentioned was the Phase I LIBELULE Study, which is a
Dr Kristof Cuppens shares his insights on key presentations of ASCO 2023. Dr. Cuppens has provided us with invaluable commentary on significant studies presented at the conference.
In-depth stories about lung cancer
In another intriguing discussion, Dr Brandao from the Institut Jules Bordet and Prof. Dr Nicolas Girard from the Institut Curie in Paris explored the implications of the latest data on
In another intriguing discussion, Dr Brandao from the Institut Jules Bordet and Prof. Dr Nicolas Girard from the Institut Curie in Paris explored the implications of the latest data on
The DICIPLE phase III study, which tested the alternative “stop and go” strategy in advanced NSCLC patients, was conducted at multiple hospitals across France. Prof. Dr. Anne-Claire Toffart, a co-author
During the second part of their engaging conversation, Professor Benjamin Besse, who heads the Cancer Medicine Department at Gustave Roussy and chairs the EORTC Lung Group, and Dr. Mariana Brandao
Dr. Brandao delved into the findings of this phase III study involving the use of chemotherapy (cisplatin and pemetrexed) and immunotherapy (pembrolizumab) as a first-line treatment for malignant pleural mesothelioma.
The plenary session at ASCO saw Prof Roy S. Herbst of the Yale Cancer Center present the overall survival analysis from the ADAURA trial on adjuvant osimertinib for patients with
The possibility of performing surgical resection for non-small-cell lung cancer following preoperative therapy involving immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 has been validated. This study presents the initial data
The CheckMate 9LA study has already demonstrated the significant benefit of combining nivolumab and ipilimumab with two cycles of chemotherapy in terms of overall survival compared to chemotherapy alone. Due
Lung cancer poster selection
The Phase III IMpower010 trial successfully demonstrated that the addition of atezolizumab following adjuvant platinum-based chemotherapy in patients with completely resected stage IB-IIIA non-small-cell lung cancer (NSCLC) led to improved
Patients with KRAS G12C-mutated advanced NSCLC often experience brain metastases, which can have a negative impact on their survival and quality of life. However, a recent global clinical trial called
PD-1 and TIGIT play a significant role in the immunosuppressive response of T cells in cancer. Rilvegostomig, a bispecific IgG1 antibody that targets both PD-1 and TIGIT, has been developed
Results from the PEARLS/KEYNOTE-091 study, a triple-blind phase 3 trial, have shown that pembrolizumab significantly improved disease-free survival in patients with completely resected stage IB-IIIA, regardless of whether they had
The CheckMate 816 study has demonstrated that neoadjuvant nivolumab + chemotherapy enhances event-free survival and pathologic complete response when compared to chemotherapy alone in patients with resectable non-small lung cancer.
Individuals diagnosed with oligometastatic NSCLC can benefit from local ablative therapy, though the impact of adjuvant systemic treatment is uncertain. During the poster session at ASCO 2023, Dr. David Cantor
Divya Natesan from the University of Pittsburgh sought to examine the frequency of using a 3-weekly versus a 6-weekly dosing of pembrolizumab in a real-world context. Additionally, she explored whether